Kratchmarov, Radomir
Djeddi, Sarah http://orcid.org/0000-0001-9446-6976
Dunlap, Garrett http://orcid.org/0000-0002-2627-0506
He, Wenqin
Jia, Xiaojiong
Burk, Caitlin M. http://orcid.org/0000-0001-7652-8248
Ryan, Tessa
McGill, Alanna
Allegretti, Jessica R.
Kataru, Raghu P. http://orcid.org/0000-0003-1315-7982
Mehrara, Babak J. http://orcid.org/0000-0001-5717-697X
Taylor, Erin M.
Agarwal, Shailesh
Bhattacharyya, Neil
Bergmark, Regan W.
Maxfield, Alice Z.
Lee, Stella http://orcid.org/0000-0001-6563-6606
Roditi, Rachel
Dwyer, Daniel F.
Boyce, Joshua A.
Buchheit, Kathleen M.
Laidlaw, Tanya M.
Shreffler, Wayne G. http://orcid.org/0000-0001-6465-137X
Rao, Deepak A. http://orcid.org/0000-0001-9672-7746
Gutierrez-Arcelus, Maria http://orcid.org/0000-0001-7898-7691
Brennan, Patrick J. http://orcid.org/0000-0003-0715-8209
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (U19AI095219, T32AI007306, U19AI095219, U19AI095219, U19AI095219, K23AI139352, U19AI095219, U19AI095219, U19AI095219)
Article History
Received: 21 January 2024
Accepted: 6 March 2024
First Online: 8 April 2024
Competing interests
: S.L. reports clinical trial funding from Sanofi Aventis Regeneron, GlaxoSmithKline, AstraZeneca and OptiNose and participated on advisory boards for GlaxoSmithKline, AstraZeneca, Sanofi Aventis, Regeneron, Genentech and Novartis. R.W.B. reports unrelated clinical trial funding from I-Mab Biopharma (CTA: HLW-ALZ-NAS-001). N.B. reports consultant fees for unrelated epidemiology research for GlaxoSmithKline. D.A.R. reports consultant fees for unrelated work from GlaxoSmithKline, AstraZeneca, Pfizer, HiFiBio Therapeutics, Scipher Medicine and Bristol-Myers Squibb and grant support unrelated to this work from Janssen, Merck and Bristol-Myers Squibb. D.F.D. reports unrelated consultant fees from Celldex Therapeutics. The other authors declare no competing interests.